Skip to main content
Premium Trial:

Request an Annual Quote

Cognia Builds on Content Experience with Data Management System; Signs Four Licensees

Premium

Cognia last week released a major upgrade of its Cognia Molecular information management system, concurrent with the announcement that it has licensed the product to BioSeek, Harvard Medical School, Yale Medical School, and the State University of New York at Binghamton.

The company launched Cognia Molecular in late 2002, but has continued improving it based on feedback from its customers, said David Rubin, Cognia CEO. These customers — numbering around 100 — have primarily been for the database products that Cognia distributes from Biobase and John Wiley & Sons. Rubin said that Cognia has collaborated closely with these users to determine their content management needs to gather ideas for Cognia Molecular. Al LiVecchi, director of marketing at the company, said that Cognia will continue to market its content products, and sees the data management system as a natural extension of its offerings in that area. Cognia Molecular “will allow users to access and analyze our content in the context of their own data,” he said.

The system is built around a relational database that allows users to integrate and manage a number of data resources. It is pre-loaded with a curated dataset of more than 100,000 proteins, genes, and interactions, and 250,000 compounds. It also includes links to more than 35 external databases. Cognia works with customers of the system to include proprietary and other third-party data, and provides an API so that users can connect their own data and applications. The system also offers curation clients, automated batch-loading tools, and FlexLoader, an application that allows users to set their own experimental parameters to configure the content that is loaded into the database.

Cognia Molecular is able to integrate various data resources, but “it’s not middleware,” Livecchi said. “It’s not shoving a whole bunch of things into one place … It takes things to the next level because people are creating their own database with it.”

The company did not disclose pricing information for the system, because it can vary based on the level of customization required. However, Rubin said, “We’re confident that we can compete with others in this market.”

— BT

Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.